Charmacy Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Charmacy Pharmaceutical has been growing earnings at an average annual rate of 16.1%, while the Healthcare industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 4.9% per year. Charmacy Pharmaceutical's return on equity is 8.7%, and it has net margins of 1.2%.
Key information
16.1%
Earnings growth rate
16.1%
EPS growth rate
| Healthcare Industry Growth | 11.3% |
| Revenue growth rate | 4.9% |
| Return on equity | 8.7% |
| Net Margin | 1.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 19These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity
Sep 17Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?
Feb 17We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide
Jan 27Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture
Jan 09What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us
Dec 22
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years
Nov 29Revenue & Expenses Breakdown
How Charmacy Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4,482 | 52 | 176 | 0 |
| 31 Mar 24 | 4,443 | 52 | 173 | 0 |
| 31 Dec 23 | 4,404 | 51 | 171 | 0 |
| 30 Sep 23 | 4,480 | 74 | 173 | 0 |
| 30 Jun 23 | 4,557 | 96 | 175 | 0 |
| 31 Mar 23 | 4,366 | 93 | 170 | 0 |
| 31 Dec 22 | 4,175 | 90 | 165 | 0 |
| 30 Sep 22 | 3,931 | 54 | 159 | 0 |
| 30 Jun 22 | 3,688 | 18 | 153 | 0 |
| 31 Mar 22 | 3,741 | 20 | 152 | 0 |
| 31 Dec 21 | 3,794 | 23 | 152 | 0 |
| 30 Sep 21 | 3,959 | 29 | 153 | 0 |
| 30 Jun 21 | 4,124 | 36 | 154 | 0 |
| 31 Mar 21 | 4,058 | 38 | 149 | 0 |
| 31 Dec 20 | 3,992 | 41 | 143 | 0 |
| 30 Sep 20 | 3,819 | 35 | 137 | 0 |
| 30 Jun 20 | 3,645 | 29 | 130 | 0 |
| 31 Mar 20 | 3,569 | 34 | 129 | 0 |
| 31 Dec 19 | 3,493 | 40 | 128 | 0 |
| 30 Sep 19 | 3,557 | 41 | 127 | 0 |
| 30 Jun 19 | 3,621 | 42 | 125 | 0 |
| 31 Mar 19 | 3,778 | 44 | 128 | 0 |
| 31 Dec 18 | 3,935 | 45 | 130 | 0 |
| 30 Sep 18 | 4,075 | 46 | 129 | 0 |
| 30 Jun 18 | 4,214 | 47 | 128 | 0 |
| 31 Mar 18 | 4,155 | 46 | 124 | 0 |
| 31 Dec 17 | 4,096 | 45 | 120 | 0 |
| 30 Sep 17 | 3,946 | 54 | 112 | 0 |
| 30 Jun 17 | 3,796 | 63 | 104 | 0 |
| 31 Mar 17 | 3,733 | 60 | 98 | 0 |
| 31 Dec 16 | 3,670 | 56 | 93 | 0 |
| 30 Sep 16 | 3,605 | 47 | 88 | 0 |
| 30 Jun 16 | 3,540 | 38 | 83 | 0 |
| 31 Mar 16 | 3,468 | 32 | 82 | 0 |
| 31 Dec 15 | 3,397 | 26 | 81 | 0 |
| 30 Sep 15 | 3,299 | 31 | 82 | 0 |
| 30 Jun 15 | 3,200 | 35 | 83 | 0 |
| 31 Mar 15 | 3,107 | 36 | 78 | 0 |
| 31 Dec 14 | 3,014 | 36 | 73 | 0 |
| 31 Dec 13 | 2,401 | 22 | 59 | 0 |
Quality Earnings: 2289 has high quality earnings.
Growing Profit Margin: 2289's current net profit margins (1.2%) are lower than last year (2.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2289's earnings have grown by 16.1% per year over the past 5 years.
Accelerating Growth: 2289's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2289 had negative earnings growth (-46.2%) over the past year, making it difficult to compare to the Healthcare industry average (-16.9%).
Return on Equity
High ROE: 2289's Return on Equity (8.7%) is considered low.